The reduction in price target from $80 to $50 by a reputable analyst firm like BMO Capital could lead to a negative short-term sentiment among investors, potentially causing a decrease in the stock price of Disc Medicine. The maintenance of an Outperform rating indicates a positive outlook on the company's fundamentals, but the significant cut in the price target may overshadow this optimism in the short term.